A New Perspective on Precision Medicine: The Power of Digital Organoids
Source abstract
Abstract
Precision medicine is a personalized medical model based on the individual’s genome, phenotype, and lifestyle that provides tailored treatment plans for patients. In this context, tumor organoids, a 3-dimensional preclinical model based on patient-derived tumor cell self-organization, combined with digital analysis methods, such as high-throughput sequencing and image processing technology, can be used to analyze the genome, transcriptome, and cellular heterogeneity of tumors, so as to accurately track and assess the growth process, genetic characteristics, and drug responsiveness of tumor organoids, thereby facilitating the implementation of precision medicine. This interdisciplinary approach is expected to promote the innovation of cancer diagnosis and enhance personalized treatment. In this review, the characteristics and culture methods of tumor organoids are summarized, and the application of multi-omics, such as bioinformatics and artificial intelligence, and the digital methods of organoids in precision medicine research are discussed. Finally, this review explores the main causes and potential solutions for the bottleneck in the clinical translation of digital tumor organoids, proposes the prospects of multidisciplinary cooperation and clinical transformation to narrow the gap between laboratory and clinical settings, and provides references for research and development in this field.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Health and Medical Research Impacts · Artificial Intelligence in Healthcare and Education
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou 310015, Zhejiang, China.
Funding
Natural Science Foundation of Hunan Province · National Natural Science Foundation of China
References (100+)
Show source-provided references
1. König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J. 2017;50(4):1700391.10.1183/13993003.00391-2017 ↗
2. 10.15252/embr.20143848010.15252/embr.201438480 ↗
3. Li J, Li X, Zhang S, Snyder M. Gene-environment interaction in the era of precision medicine. Cell. 2019;177(1):38–44.10.1016/j.cell.2019.03.004 ↗
4. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, et al. Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study. Nat Med. 2019;25(5):744–750.10.1038/s41591-019-0407-5 ↗
5. 10.1038/s41591-019-0424-410.1038/s41591-019-0424-4 ↗
6. Foo MA, You M, Chan SL, Sethi G, Bonney GK, Yong WP, Chow EKH, Fong ELS, Wang L, Goh BC. Clinical translation of patient-derived tumour organoids—Bottlenecks and strategies. Biomark Res. 2022;10(1):10.10.1186/s40364-022-00356-6 ↗
7. 10.1016/j.ccell.2021.07.02010.1016/j.ccell.2021.07.020 ↗
8. Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis ML, Addario A, Costantini M, Flex E, Ciolfi A, Pizzi S, et al. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis. 2019;10(3):201.10.1038/s41419-019-1453-0 ↗
9. Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, et al. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J Exp Clin Cancer Res. 2023;42(1):260.10.1186/s13046-023-02809-8 ↗
10. 10.1038/ncb331210.1038/ncb3312 ↗
11. 10.3390/cells805047010.3390/cells8050470 ↗
12. Yang Q, Li M, Yang X, Xiao Z, Tong X, Tuerdi A, Li S, Lei L. Flourishing tumor organoids: History, emerging technology, and application. Bioeng Transl Med. 2023;8(5): Article e10559.10.1002/btm2.10559 ↗
13. 10.1136/gutjnl-2019-32001910.1136/gutjnl-2019-320019 ↗
14. 10.1016/j.molmed.2017.02.00710.1016/j.molmed.2017.02.007 ↗
15. 10.1126/science.124712510.1126/science.1247125 ↗
16. Durinikova E, Buzo K, Arena S. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: Past and future challenges. J Exp Clin Cancer Res. 2021;40(1):185.10.1186/s13046-021-01981-z ↗
17. 10.1016/j.copbio.2018.11.00210.1016/j.copbio.2018.11.002 ↗
18. Hof L, Moreth T, Koch M, Liebisch T, Kurtz M, Tarnick J, Lissek SM, Verstegen MMA, van der Laan LJW, Huch M, et al. Long-term live imaging and multiscale analysis identify heterogeneity and core principles of epithelial organoid morphogenesis. BMC Biol. 2021;19(1):37.10.1186/s12915-021-00958-w ↗
19. 10.1038/s43018-024-00882-210.1038/s43018-024-00882-2 ↗
20. 10.1038/s41568-024-00754-y10.1038/s41568-024-00754-y ↗
21. Mao Y, Hu H. Establishment of advanced tumor organoids with emerging innovative technologies. Cancer Lett. 2024;598: Article 217122.10.1016/j.canlet.2024.217122 ↗
22. Chen W, Liu X, Wang H, Dai J, Li C, Hao Y, Jiang D. Exploring the immune escape mechanisms in gastric cancer patients based on the deep AI algorithms and single-cell sequencing analysis. J Cell Mol Med. 2024;28(10): Article e18379.10.1111/jcmm.18379 ↗
23. 10.1111/cas.1539610.1111/cas.15396 ↗
24. Bian X, Li G, Wang C, Liu W, Lin X, Chen Z, Cheung M, Luo X. A deep learning model for detection and tracking in high-throughput images of organoid. Comput Biol Med. 2021;134: Article 104490.10.1016/j.compbiomed.2021.104490 ↗
25. 10.1002/mds.2877510.1002/mds.28775 ↗
26. 10.1007/s12539-020-00386-410.1007/s12539-020-00386-4 ↗
27. Gunnarsson EB, Kim S, Choi B, Schmid JK, Kaura K, Lenz HJ, Mumenthaler SM, Foo J. Understanding patient-derived tumor organoid growth through an integrated imaging and mathematical modeling framework. PLOS Comput Biol. 2024;20(8): Article e1012256.10.1371/journal.pcbi.1012256 ↗
28. Ortiz MMO, Andrechek ER. Molecular characterization and landscape of breast cancer models from a multi-omics perspective. J Mammary Gland Biol Neoplasia. 2023;28(1):12.10.1007/s10911-023-09540-2 ↗
29. Chew NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, Yang J, Hui MN, Deng N, McLean CA, Welm AL, Lim E, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Res. 2021;23(1):82.10.1186/s13058-021-01461-4 ↗
30. Chen L, Dai Z, Zhang Y, Sheng H, Hu B, Du J, Chang J, Xu W, Hu Y. Integrative metabolome and transcriptome analyses provide insights into PHGDH in colon cancer organoids. Biosci Rep. 2025;45(1):1–12.10.1042/BSR20240842 ↗
31. Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11(1):116.10.1186/s13045-018-0662-9 ↗
32. 10.1016/j.ccell.2021.01.00510.1016/j.ccell.2021.01.005 ↗
33. Nagle PW, Plukker JTM, Muijs CT, van Luijk P, Coppes RP. Patient-derived tumor organoids for prediction of cancer treatment response. Semin Cancer Biol. 2018;53(1):258–264.10.1016/j.semcancer.2018.06.005 ↗
34. Golebiewska A, Fields RC. Advancing preclinical cancer models to assess clinically relevant outcomes. BMC Cancer. 2023;23(1):230.10.1186/s12885-023-10715-7 ↗
35. 10.1038/nrc397210.1038/nrc3972 ↗
36. 10.1038/ng.396710.1038/ng.3967 ↗
37. Cho SY, Sung CO, Chae J, Lee J, Na D, Kang W, Kang J, Min S, Lee A, Kwak E, et al. Alterations in the rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. Blood. 2018;131(17):1931–1941.10.1182/blood-2017-07-797209 ↗
38. 10.1007/s10147-019-01520-z10.1007/s10147-019-01520-z ↗
39. 10.1016/j.cell.2016.05.08210.1016/j.cell.2016.05.082 ↗
40. Dai X, Wang X, Yang C, Huang M, Zhou Z, Qu Y, Cui X, Liu R, Chen C. Human fibroblasts facilitate the generation of iPSCs-derived mammary-like organoids. Stem Cell Res Ther. 2022;13(1):377.10.1186/s13287-022-03023-7 ↗
41. 10.1016/j.jhep.2019.06.03010.1016/j.jhep.2019.06.030 ↗
42. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, Ellis E, van Wenum M, Fuchs SA, de Ligt J, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160(1-2):299–312.10.1016/j.cell.2014.11.050 ↗
43. 10.1016/j.stem.2020.10.01410.1016/j.stem.2020.10.014 ↗
44. 10.1158/0008-5472.CAN-15-240210.1158/0008-5472.CAN-15-2402 ↗
45. 10.1016/j.cell.2020.10.02310.1016/j.cell.2020.10.023 ↗
46. 10.1016/j.cell.2017.11.01010.1016/j.cell.2017.11.010 ↗
47. 10.1038/nm.380210.1038/nm.3802 ↗
48. Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424–1435.10.1038/nm.4438 ↗
49. Tamura H, Higa A, Hoshi H, Hiyama G, Takahashi N, Ryufuku M, Morisawa G, Yanagisawa Y, Ito E, Imai JI, et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncol Rep. 2018;40(2):635–646.
50. 10.1126/science.aao277410.1126/science.aao2774 ↗
51. 10.1016/j.cell.2018.11.02110.1016/j.cell.2018.11.021 ↗
52. Thng DKH, Hooi L, Siew BE, Lee KY, Tan IJ, Lieske B, Lin NS, Kow AWC, Wang S, Rashid MBMA, et al. A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids. NPJ Precis Oncol. 2024;8(1):52.10.1038/s41698-024-00543-8 ↗
53. Nguyen-Ngoc KV, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC, Yaswen P, Werb Z, Ewald AJ. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc Natl Acad Sci USA. 2012;109(39):E2595–E2604.
54. Talbot NC, Caperna TJ. Proteome array identification of bioactive soluble proteins/peptides in Matrigel: Relevance to stem cell responses. Cytotechnology. 2015;67(5):873–883.10.1007/s10616-014-9727-y ↗
55. El-Derby AM, Khedr MA, Ghoneim NI, Gabr MM, Khater SM, El-Badri N. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma. J Transl Med. 2024;22(1):487.10.1186/s12967-024-05230-7 ↗
56. Cassereau L, Miroshnikova YA, Ou G, Lakins J, Weaver VM. A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype. J Biotechnol. 2015;193:66–69.10.1016/j.jbiotec.2014.11.008 ↗
57. 10.1038/nature2016810.1038/nature20168 ↗
58. 10.1038/s41586-020-3034-x10.1038/s41586-020-3034-x ↗
59. 10.1038/s41563-021-01057-510.1038/s41563-021-01057-5 ↗
60. 10.1016/j.cell.2015.03.05310.1016/j.cell.2015.03.053 ↗
61. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176–187.10.1016/j.cell.2014.08.016 ↗
62. 10.1016/j.cell.2019.11.03610.1016/j.cell.2019.11.036 ↗
63. Li X, Francies HE, Secrier M, Perner J, Miremadi A, Galeano-Dalmau N, Barendt WJ, Letchford L, Leyden GM, Goffin EK, et al. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat Commun. 2018;9(1):2983.10.1038/s41467-018-05190-9 ↗
64. 10.1016/j.cell.2018.03.01710.1016/j.cell.2018.03.017 ↗
65. 10.1016/j.stem.2018.09.01610.1016/j.stem.2018.09.016 ↗
66. 10.1038/ncb351610.1038/ncb3516 ↗
67. 10.1083/jcb.20110214710.1083/jcb.201102147 ↗
68. 10.1083/jcb.20080702110.1083/jcb.200807021 ↗
69. Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development. 1989;105(2):223–235.10.1242/dev.105.2.223 ↗
70. 10.1038/nrc397110.1038/nrc3971 ↗
71. Xu R, Zhou X, Wang S, Trinkle C. Tumor organoid models in precision medicine and investigating cancer-stromal interactions. Pharmacol Ther. 2021;218: Article 107668.10.1016/j.pharmthera.2020.107668 ↗
72. 10.1038/s41556-022-00969-x10.1038/s41556-022-00969-x ↗
73. Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in cancer research. EMBO J. 2019;38(15): Article e101654.10.15252/embj.2019101654 ↗
74. 10.1016/j.cell.2017.01.00210.1016/j.cell.2017.01.002 ↗
75. Prasad CP, Tripathi SC, Kumar M, Mohapatra P. Passage number of cancer cell lines: Importance, intricacies, and way-forward. Biotechnol Bioeng. 2023;120(8):2049–2055.10.1002/bit.28496 ↗
76. Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, Gadellaa-van Hooijdonk CGM, van der Velden DL, Peeper DS, Cuppen EPJG, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci USA. 2015;112(43):13308–13311.10.1073/pnas.1516689112 ↗
77. 10.1158/1078-0432.CCR-19-363710.1158/1078-0432.CCR-19-3637 ↗
78. 10.1016/j.bioactmat.2023.09.00510.1016/j.bioactmat.2023.09.005 ↗
79. 10.1126/scitranslmed.adg335810.1126/scitranslmed.adg3358 ↗
80. 10.1016/j.cell.2022.09.03110.1016/j.cell.2022.09.031 ↗
81. Codrich M, Dalla E, Mio C, Antoniali G, Malfatti MC, Marzinotto S, Pierobon M, Baldelli E, di Loreto C, Damante G, et al. Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN. J Exp Clin Cancer Res. 2021;40(1):198.10.1186/s13046-021-01986-8 ↗
82. Papaccio F, García-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutiérrez-Bravo MF, Alfaro-Cervelló C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zúñiga-Trejos S, et al. Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. J Exp Clin Cancer Res. 2023;42(1):8.10.1186/s13046-022-02591-z ↗
83. Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017;8:14262.10.1038/ncomms14262 ↗
84. Lindstrand A, Eisfeldt J, Pettersson M, Carvalho CMB, Kvarnung M, Grigelioniene G, Anderlid BM, Bjerin O, Gustavsson P, Hammarsjö A, et al. From cytogenetics to cytogenomics: Whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability. Genome Med. 2019;11(1):68.10.1186/s13073-019-0675-1 ↗
85. 10.1038/nature2012310.1038/nature20123 ↗
86. Wang R, Mao Y, Wang W, Zhou X, Wang W, Gao S, Li J, Wen L, Fu W, Tang F. Systematic evaluation of colorectal cancer organoid system by single-cell RNA-seq analysis. Genome Biol. 2022;23(1):106.10.1186/s13059-022-02673-3 ↗
87. 10.1038/s41586-018-0024-310.1038/s41586-018-0024-3 ↗
88. 10.1038/s41591-019-0422-610.1038/s41591-019-0422-6 ↗
89. Zhao Y, Li ZX, Zhu YJ, Fu J, Zhao XF, Zhang YN, Wang S, Wu JM, Wang KT, Wu R, et al. Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. Adv Sci. 2021;8(11): Article e2003897.10.1002/advs.202003897 ↗
90. 10.1093/neuonc/noaa09110.1093/neuonc/noaa091 ↗
91. Norkin M, Ordóñez-Morán P, Huelsken J. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer. Cell Rep. 2021;35(3): Article 109026.10.1016/j.celrep.2021.109026 ↗
92. 10.1016/j.ebiom.2019.03.06410.1016/j.ebiom.2019.03.064 ↗
93. Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69S:S36–S40.10.1016/j.metabol.2017.01.011 ↗
94. Han X, Cai C, Deng W, Shi Y, Li L, Wang C, Zhang J, Rong M, Liu J, Fang B, et al. Landscape of human organoids: Ideal model in clinics and research. Innovation. 2024;5(3): Article 100620.
95. Maramraju S, Kowalczewski A, Kaza A, Liu X, Singaraju JP, Albert MV, Ma Z, Yang H. AI-organoid integrated systems for biomedical studies and applications. Bioeng Transl Med. 2024;9(2): Article e10641.10.1002/btm2.10641 ↗
96. 10.1038/s41576-019-0122-610.1038/s41576-019-0122-6 ↗
97. 10.1016/j.jacc.2018.03.52110.1016/j.jacc.2018.03.521 ↗
98. 10.1038/s41588-018-0295-510.1038/s41588-018-0295-5 ↗
99. 10.1038/s41586-021-04357-710.1038/s41586-021-04357-7 ↗
100. 10.1038/nature1251710.1038/nature12517 ↗